Annual CFF
$81.66 M
-$15.88 M-16.29%
December 31, 2022
Summary
- As of February 8, 2025, EVLO annual cash flow from financing activities is $81.66 million, with the most recent change of -$15.88 million (-16.29%) on December 31, 2022.
- During the last 3 years, EVLO annual CFF has risen by +$76.66 million (+1535.72%).
- EVLO annual CFF is now -49.60% below its all-time high of $162.01 million, reached on December 31, 2018.
Performance
EVLO Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$19.22 M
+$19.22 M+100.00%
September 30, 2023
Summary
- As of February 8, 2025, EVLO quarterly cash flow from financing activities is $19.22 million, with the most recent change of +$19.22 million (+100.00%) on September 30, 2023.
- Over the past year, EVLO quarterly CFF has increased by +$18.55 million (+2790.23%).
- EVLO quarterly CFF is now -77.49% below its all-time high of $85.38 million, reached on March 31, 2018.
Performance
EVLO Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$20.76 M
+$18.55 M+841.50%
September 30, 2023
Summary
- As of February 8, 2025, EVLO TTM cash flow from financing activities is $20.76 million, with the most recent change of +$18.55 million (+841.50%) on September 30, 2023.
- Over the past year, EVLO TTM CFF has dropped by -$59.03 million (-73.98%).
- EVLO TTM CFF is now -87.23% below its all-time high of $162.51 million, reached on June 30, 2018.
Performance
EVLO TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
EVLO Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -16.3% | +2790.2% | -74.0% |
| 3 y3 years | +1535.7% | +94.4% | -64.8% |
| 5 y5 years | +66.8% | +4038.5% | +315.9% |
EVLO Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -16.3% | at low | -75.7% | +9758.3% | -78.7% | +841.5% |
| 5 y | 5-year | -16.3% | +1535.7% | -76.7% | +9758.3% | -85.9% | +841.5% |
| alltime | all time | -49.6% | +1535.7% | -77.5% | +4038.5% | -87.2% | +7875.3% |
Evelo Biosciences Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2023 | - | $19.22 M(>+9900.0%) | $20.76 M(+841.5%) |
| Jun 2023 | - | $0.00(-100.0%) | $2.21 M(-97.3%) |
| Mar 2023 | - | -$199.00 K(-111.4%) | $81.34 M(-0.4%) |
| Dec 2022 | $81.66 M(-16.3%) | $1.74 M(+161.5%) | $81.66 M(+2.3%) |
| Sep 2022 | - | $665.00 K(-99.2%) | $79.79 M(+0.4%) |
| Jun 2022 | - | $79.13 M(>+9900.0%) | $79.46 M(+418.3%) |
| Mar 2022 | - | $117.00 K(-192.9%) | $15.33 M(-84.3%) |
| Dec 2021 | $97.54 M(+49.0%) | -$126.00 K(-138.1%) | $97.54 M(-6.5%) |
| Sep 2021 | - | $331.00 K(-97.8%) | $104.37 M(-8.4%) |
| Jun 2021 | - | $15.01 M(-81.8%) | $113.92 M(-22.8%) |
| Mar 2021 | - | $82.33 M(+1128.4%) | $147.57 M(+125.4%) |
| Dec 2020 | $65.47 M | $6.70 M(-32.2%) | $65.47 M(+11.0%) |
| Sep 2020 | - | $9.89 M(-79.7%) | $58.99 M(+9.9%) |
| Jun 2020 | - | $48.65 M(>+9900.0%) | $53.66 M(+982.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | $226.00 K(-1.3%) | $4.96 M(-0.6%) |
| Dec 2019 | $4.99 M(-96.9%) | $229.00 K(-95.0%) | $4.99 M(+4.4%) |
| Sep 2019 | - | $4.56 M(-8390.9%) | $4.78 M(-1890.6%) |
| Jun 2019 | - | -$55.00 K(-121.3%) | -$267.00 K(-100.3%) |
| Mar 2019 | - | $258.00 K(+1333.3%) | $76.89 M(-52.5%) |
| Dec 2018 | $162.01 M(+230.9%) | $18.00 K(-103.7%) | $162.01 M(+0.0%) |
| Sep 2018 | - | -$488.00 K(-100.6%) | $162.00 M(-0.3%) |
| Jun 2018 | - | $77.10 M(-9.7%) | $162.51 M(+59.5%) |
| Mar 2018 | - | $85.38 M(>+9900.0%) | $101.87 M(+108.0%) |
| Dec 2017 | $48.97 M(+211.1%) | $8000.00(-52.9%) | $48.97 M(+0.0%) |
| Sep 2017 | - | $17.00 K(-99.9%) | $48.96 M(+0.0%) |
| Jun 2017 | - | $16.46 M(-49.3%) | $48.94 M(+50.7%) |
| Mar 2017 | - | $32.48 M | $32.48 M |
| Dec 2016 | $15.74 M | - | - |
FAQ
- What is Evelo Biosciences annual cash flow from financing activities?
- What is the all time high annual CFF for Evelo Biosciences?
- What is Evelo Biosciences annual CFF year-on-year change?
- What is Evelo Biosciences quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Evelo Biosciences?
- What is Evelo Biosciences quarterly CFF year-on-year change?
- What is Evelo Biosciences TTM cash flow from financing activities?
- What is the all time high TTM CFF for Evelo Biosciences?
- What is Evelo Biosciences TTM CFF year-on-year change?
What is Evelo Biosciences annual cash flow from financing activities?
The current annual CFF of EVLO is $81.66 M
What is the all time high annual CFF for Evelo Biosciences?
Evelo Biosciences all-time high annual cash flow from financing activities is $162.01 M
What is Evelo Biosciences annual CFF year-on-year change?
Over the past year, EVLO annual cash flow from financing activities has changed by -$15.88 M (-16.29%)
What is Evelo Biosciences quarterly cash flow from financing activities?
The current quarterly CFF of EVLO is $19.22 M
What is the all time high quarterly CFF for Evelo Biosciences?
Evelo Biosciences all-time high quarterly cash flow from financing activities is $85.38 M
What is Evelo Biosciences quarterly CFF year-on-year change?
Over the past year, EVLO quarterly cash flow from financing activities has changed by +$18.55 M (+2790.23%)
What is Evelo Biosciences TTM cash flow from financing activities?
The current TTM CFF of EVLO is $20.76 M
What is the all time high TTM CFF for Evelo Biosciences?
Evelo Biosciences all-time high TTM cash flow from financing activities is $162.51 M
What is Evelo Biosciences TTM CFF year-on-year change?
Over the past year, EVLO TTM cash flow from financing activities has changed by -$59.03 M (-73.98%)